Home » Press Releases

Dyadic’s President and CEO, Mark Emalfarb, stated “The data supporting this product clearly demonstrates Dyadic’s scientific capabilities to leverage our C1 technology platform to create enzyme mixtures whose performance rivals the leading biofuels enzyme product on the market. This is largely due to the inherent robustness and versatility of the C1 genome and expression system, both of which have considerable untapped potential. The results obtained with AlternaFuel® CMAX3™ are not only relevant for the production of biofuels but also for bio-based chemicals and biogas. Dyadic and its licensees are continuing to develop better performing enzymes to further reduce the total cost of producing advanced biofuels and other bio-based products.”

Jan Wery, Science Director at Dyadic Netherlands, added, “AlternaFuel® CMAX3™ achieved a similar saccharification yield at pH 5.0 and substantially better results at pH 6.0 than those achieved by the current leading competitive biofuels enzyme product. Saccharification yield is defined as the relative amount of fermentable sugars released through enzymatic hydrolysis from lignocellulosic biomass such as agricultural feedstock and waste. This important parameter demonstrates the level of progress being made across the entire industrial enzyme industry in developing enzymes necessary for lignocellulosic biomass to replace petroleum in fuel and chemical production.”

About AlternaFuel® CMAX3™

AlternaFuel® CMAX3™is the latest generation of a cellulase and hemicellulase complex based on Dyadic’s C1 platform technology which enables efficient conversion of multiple forms of non-food biomass into fermentable sugars at broad pH and temperature ranges that can be used to produce biofuels, bio-based chemicals, biogas and other bio-based products.

For more information on AlternaFuel® CMAX3™, please visit Dyadic’s recently remodeled website at www.dyadic.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary C1 fungal production platform and other technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the proteins which these technologies help produce.

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that conducts research and development activities for the benefit of Dyadic, its collaborators and customers.  Please visit Dyadic Netherland’s website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

Contact:

Thomas M. O’Shaughnessy

Vice President Sales & Marketing

Dyadic International, Inc.

Phone: 561-743-8333

Email: enzymes@dyadic.com